Factor VIIa inhibitors: improved pharmacokinetic parameters.
Efforts to improve the potency and pharmacokinetic properties of small molecule factor VIIa inhibitors are described. Small structural modifications to existing leads allow the modulation of half-life and clearance, potentially making these compounds suitable candidates for drug development.
Kolesnikov
Aleksandr
A
Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA. kolesnikov@yahoo.com
Rai
Roopa
R
Young
Wendy B
WB
Mordenti
Joyce
J
Liu
Liang
L
Torkelson
Steven
S
Shrader
William D
WD
Leahy
Ellen M
EM
Hu
Huiyong
H
Gjerstad
Erik
E
Janc
James
J
Katz
Bradley A
BA
Sprengeler
Paul A
PA
D000818:Animals; D000925:Anticoagulants / Q000493:pharmacokinetics*; D001777:Blood Coagulation / Q000187:drug effects*; D015195:Drug Design; D015942:Factor VIIa / Q000037:antagonists & inhibitors*; D006207:Half-Life; D006801:Humans; D015394:Molecular Structure; D015842:Serine Proteinase Inhibitors / Q000493:pharmacokinetics*; D013329:Structure-Activity Relationship
D000925:Anticoagulants; D015842:Serine Proteinase Inhibitors; D015942:Factor VIIa